BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21941193)

  • 21. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
    Rosh JR; Oliva-Hemker M
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):165-7. PubMed ID: 17255825
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.
    Mackey AC; Green L; Leptak C; Avigan M
    J Pediatr Gastroenterol Nutr; 2009 Mar; 48(3):386-8. PubMed ID: 19274799
    [No Abstract]   [Full Text] [Related]  

  • 24. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.
    Brown SL; Greene MH; Gershon SK; Edwards ET; Braun MM
    Arthritis Rheum; 2002 Dec; 46(12):3151-8. PubMed ID: 12483718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
    Keane J; Gershon S; Wise RP; Mirabile-Levens E; Kasznica J; Schwieterman WD; Siegel JN; Braun MM
    N Engl J Med; 2001 Oct; 345(15):1098-104. PubMed ID: 11596589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
    Martín De Carpi J; Varea V
    An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatosplenic T cell lymphoma in inflammatory bowel disease.
    Shale M; Kanfer E; Panaccione R; Ghosh S
    Gut; 2008 Dec; 57(12):1639-41. PubMed ID: 18667489
    [No Abstract]   [Full Text] [Related]  

  • 32. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
    Moran G; Dillon J; Green J
    Inflamm Bowel Dis; 2009 Sep; 15(9):1281-2. PubMed ID: 19067412
    [No Abstract]   [Full Text] [Related]  

  • 33. Lymphomas in two IBD patients treated with anti-TNF-α mono or combination therapy: is hepatosplenic lymphoma really the "old maid"?
    Molnár T; Farkas K; Nagy F; Szepes Z; Wittmann T
    Inflamm Bowel Dis; 2011 Sep; 17(9):2025-6. PubMed ID: 21290481
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.
    Yabe M; Medeiros LJ; Tang G; Wang SA; Ahmed S; Nieto Y; Hu S; Bhagat G; Oki Y; Patel KP; Routbort M; Luthra R; Fanale MA; Bueso-Ramos CE; Jorgensen JL; Vega F; Chen W; Hoehn D; Konoplev S; Milton DR; Wistuba I; Li S; You MJ; Young KH; Miranda RN
    Am J Surg Pathol; 2016 May; 40(5):676-88. PubMed ID: 26872013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.